BK virus (BKV) was first isolated in 1971 from the urine of a renal allograft patient (13) . Since then, it has become apparent that BKV and another papovavirus, JC virus, are independently circulating in the human population. Serological surveys have shown that both viruses are found worldwide and that primary infection occurs most commonly in childhood (7, 12, 18, 23) . Urine is the only known route of excretion of human papovaviruses, although the virus has been found in brains of patients with progressive multifocal leukoencephalopathy (1) . Studies of renal allograft and bone marrow transplantation patients have shown that BKV is reactivated in patients with reduced immunocompetence (5, 16, 22, 25) . BKV has been found in the urine of immunocompromised patients (2) , including patients with congenital immunodeficiencies (26, 31) , acquired immunodeficiency syndrome patients (8) , and patients receiving therapy for malignancy (10, 25) . Recently, BKV DNA has been found in Kaposi's sarcoma tissue (3) , and receptors for BKV have been found on lymphocytes (24) . Serological studies have shown that pregnant women may have a primary or reactivated BKV infection (6) , and this has raised the question of in utero papovavirus infection. Polyomavirus is transmitted transplacentally in mice (19) , but evidence for transplacental transmission of polyomavirus in humans is contradictory (6, 14, 26, 28, 30) and there have been no confirmed reports of in utero infection in humans.
Infections with human polyomaviruses are difficult to diagnose since wild-type strains of human polyomaviruses require passage before they will grow in conventional cell culture, making primary isolation an impractical approach. To date, serology has been much more useful than virus isolation. Seroconversion, fourfold increases in immunoglobulin G (IgG) antibody titers between acute-and conva-* Corresponding author. lescent-phase sera, and detection of specific IgM antibody have been used for diagnosing BKV infections. Detection of papovavirus-specific IgM was first performed by sucrose density gradient (SDG) separation followed by hemagglutination inhibition (HI) or by indirect immunofluorescence using virus-infected cell cultures (10, 27 Antigen capture EIA. Purified BKV antigen was used to coat 96-well microdilution plates as described previously for the radioimmunoassay (RIA) (32) . Culture supernatant fluid with a hemagglutination titer of 1:4,096 was also used to coat microdilution plates for some experiments. All reagent volumes were 50 fil. HEK cell lysate was used at an equivalent protein concentration (-1 Fig/ml ) to coat parallel wells to assess nonspecific antibody binding. Doubling dilutions of sera starting at 1:200 were prepared by using buffer G as the diluent (17) , and sera were incubated for 3 h at 37°C. BKV IgM antibody was detected with horseradish peroxidaseconjugated goat anti-human IgM antibody diluted 1:400 in buffer G (1 h at 37°C). ortho-Phenylenediamine substrate and 3 N HCl (50 tl) stop solution were used as described previously (17 Fig. 1 . BKV IgM titers were 1:1,600, 1:800, and 1:200 for antigen capture (Fig. 1A) and 1:25,600, 1:6,400, and 1:1,600 for antibody capture EIA (Fig. 1B1) The specificity of the EIAs for BKV IgM was assessed by testing sera from patients with other viral infections, including four with rubella virus, two with cytomegalovirus, three with hepatitis B virus, three with hepatitis A virus, and two with JC virus. All 14 serum samples containing IgM antibody to these other viruses were negative for BKV IgM antibody by both EIAs (data not shown).
The performance of the two EIAs was compared with RIA by testing sera from renal allograft recipients with BKV infections. Of 37 serum samples, 15 had BKV IgM antibody; 14 were positive by RIA and 11 were positive by each EIA (Table 2) . Thirteen sera were negative by all three tests (eight of these were included in Table 2 ). The geometric mean titer of positive sera tested by antibody capture EIA was 9,657, compared with 11,745 for RIA and 2,718 for antigen capture EIA. Using RIA as the standard, the sensitivities (78.6%), specificities (100%), positive predictive values (100%), and negative predictive values (88.5%) for both EIAs were identical.
DISCUSSION
We have developed antigen capture and antibody capture EIAs for the detection of BKV IgM antibody. Both EIAs detected BKV IgM antibody in sera from renal allograft recipients with reactivated BKV infections, and results for both EIAs were comparable with results obtained with RIA. RF produced false-positive results in both antigen capture EIA and RIA but not in the antibody capture EIA. The RIA appeared to be more sensitive than both EIAs, detecting three additional sera with low levels of BKV IgM antibody.
The development of solid-phase antigen capture EIAs and RIAs for the measurement of specific IgM antibody has provided a significant advantage over the measurement of viral IgM antibody by traditional methods, including SDG fractionation followed by HI; however, these assays are not without problems. Sera from patients with immunological abnormalities, including anti-nuclear antibody, anti-smooth muscle antibody, or multiple myeloma, have been shown to cause false-positive rubella virus IgM results with antigen capture assays (4) . The sensitivity of these assays depends upon a high proportion of virus-specific IgM antibody in sera, since other IgM-class antibody, including RF, can reduce the sensitivity of antibody capture EIAs by competing with virus-specific IgM for binding sites on the solid phase. RF bound to the solid phase has been shown to produce false-positive results in a number of different assays (11, 15, 20, 32) . This may occur as a result of RF binding enzyme-labeled antiviral antibodies directly or by complexing with serum antiviral IgG antibodies which bind viral antigen (11) . RF interference has therefore necessitated the removal of IgG antibody by treatment with either staphylococcal protein A, aggregated IgG, or IgG-coated latex particles prior to testing (4, 11, 29, 32) . Additional approaches for improving specificity have included the use of purified viral antigen to eliminate false-positive IgM results obtained with crude antigens (11, 28, 29) and the use of a control (9) . They also found that high levels of RF and BKV IgG antibody caused false-positives in the antigen capture EIA but not in the antibody capture EIA. In contrast to our findings, they found that a solid-phase antigen capture ELISA appeared to be more sensitive than the antibody capture ELISA or SDG fractionation followed by HI; solidphase antigen capture ELISA detected 17 positive specimens, compared with 9 by antibody capture ELISA and 10 
